11/6/2025
Lilly and Novo Slash Obesity Drug Prices in Landmark Deal With Trump Administration
Eli Lilly & Co. and Novo Nordisk A/S have reached a sweeping agreement with the Trump administration to cut the prices of their blockbuster obesity drugs in exchange for tariff relief and expanded Medicare access — a move poised to reshape both the weight-loss market and broader healthcare policy in the U.S.
0
3 min read